Ser1991

Site Information
RQQRkRVsLEPHQGP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 487347
Available spectra: 6 CST

In vivo Characterization
Methods used to characterize site in vivo:	2D analysis ( 23 ) , [32P] ATP in vitro ( 23 ) , immunoassay ( 23 ) , immunoprecipitation ( 4 ) , mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 ) , mass spectrometry (in vitro) ( 23 ) , mutation of modification site ( 4 , 23 ) , phospho-antibody ( 4 ) , western blotting ( 4 )
Disease tissue studied:	breast cancer ( 5 , 7 , 8 , 26 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, surrounding tissue ( 3 ) , breast cancer, triple negative ( 3 , 7 ) , cervical cancer ( 42 ) , cervical adenocarcinoma ( 42 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 25 ) , acute myeloblastic leukemia, without maturation (M1) ( 25 ) , lung cancer ( 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 26 , 32 ) , non-small cell lung cancer ( 12 , 13 , 14 , 16 , 17 , 18 , 21 , 22 , 26 ) , non-small cell lung adenocarcinoma ( 12 , 13 , 14 , 15 , 16 , 17 , 18 , 22 ) , non-small cell large cell lung carcinoma ( 13 , 16 ) , non-small cell squamous cell lung carcinoma ( 15 ) , small-cell lung cancer ( 10 , 11 ) , B cell lymphoma ( 25 ) , non-Hodgkin's lymphoma ( 25 ) , pancreatic ductal adenocarcinoma ( 9 ) , multiple myeloma ( 25 ) , prostate cancer ( 23 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 9 ) , 293 (epithelial) ( 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ) , A549 (pulmonary) ( 12 ) , breast ( 3 , 7 ) , BT-474 (breast cell) ( 5 ) , BT-549 (breast cell) ( 26 ) , Cal-12T (pulmonary) ( 18 ) , Calu 6 (pulmonary) ( 26 ) , Calu-3 (pulmonary) ( 14 ) , CL1-0 (pulmonary) ( 32 ) , CL1-1 (pulmonary) ( 32 ) , CL1-2 (pulmonary) ( 32 ) , CL1-5 (pulmonary) ( 32 ) , CTS (myeloid) ( 25 ) , DMS153 (pulmonary) ( 17 ) , DMS53 (pulmonary) ( 11 ) , DMS79 (pulmonary) ( 10 ) , DOHH2 ('B lymphocyte, precursor') ( 25 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 27 ) , Flp-In T-Rex-293 (epithelial) ( 27 ) , H2077 (pulmonary) ( 26 ) , H322M (pulmonary) ( 26 ) , HCC1359 (pulmonary) ( 26 ) , HCC15 (pulmonary) ( 15 ) , HCC2279 (pulmonary) ( 26 ) , HCC366 (pulmonary) ( 26 ) , HCC4006 (pulmonary) ( 26 ) , HCC44 (pulmonary) ( 18 ) , HCC78 (pulmonary) ( 16 , 26 ) , HCC827 (pulmonary) ( 14 , 26 ) , HeLa (cervical) ( 2 , 4 , 6 , 24 , 29 , 31 , 45 , 46 ) , HeLa S3 (cervical) [PLK1 (human), knockdown, Tet-inducible PLK1 siRNA] ( 30 ) , HeLa S3 (cervical) ( 30 , 42 , 43 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 8 ) , HMLER ('stem, breast cancer') ( 8 ) , Jurkat (T lymphocyte) ( 19 , 41 , 44 ) , K562 (erythroid) ( 24 ) , LCLC-103H (pulmonary) ( 26 ) , LOU-NH91 (squamous) ( 15 ) , lung ( 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ) , MCF-7 (breast cell) ( 5 ) , MDA-MB-231 (breast cell) ( 26 ) , MV4-11 (macrophage) ( 25 ) , NCI-H128 (pulmonary) ( 10 ) , NCI-H1299 (pulmonary) ( 13 ) , NCI-H1355 (pulmonary) ( 12 ) , NCI-H1417 (pulmonary) ( 10 ) , NCI-H1437 (pulmonary) ( 17 , 18 ) , NCI-H157 (pulmonary) ( 26 ) , NCI-H1648 (pulmonary) ( 26 ) , NCI-H1650 (pulmonary) ( 14 ) , NCI-H1666 (pulmonary) ( 18 , 26 ) , NCI-H1703 (squamous) ( 15 ) , NCI-H1734 (pulmonary) ( 13 ) , NCI-H1781 (pulmonary) ( 16 ) , NCI-H1792 (pulmonary) ( 12 ) , NCI-H1944 (pulmonary) ( 13 ) , NCI-H1975 (pulmonary) ( 14 ) , NCI-H2073 (pulmonary) ( 15 , 17 ) , NCI-H209 (pulmonary) ( 10 , 17 ) , NCI-H2106 (pulmonary) ( 14 ) , NCI-H2172 (pulmonary) ( 26 ) , NCI-H2228 (pulmonary) ( 16 , 22 ) , NCI-H23 (pulmonary) ( 12 ) , NCI-H2342 (pulmonary) ( 15 ) , NCI-H2405 (pulmonary) ( 18 ) , NCI-H3122 (pulmonary) ( 16 , 21 ) , NCI-H358 (pulmonary) ( 13 ) , NCI-H441 (pulmonary) ( 12 ) , NCI-H446 (pulmonary) ( 11 ) , NCI-H460 (pulmonary) ( 13 ) , NCI-H524 (pulmonary) ( 10 ) , NCI-H526 (pulmonary) ( 11 ) , NCI-H661 (pulmonary) ( 16 ) , NCI-H69 (pulmonary) ( 11 ) , NCI-H82 (pulmonary) ( 11 ) , NCI-H838 (pulmonary) ( 17 ) , OPM-2 (plasma cell) ( 25 ) , P31/FUJ (erythroid) ( 25 ) , PC3 (prostate cell) ( 23 ) , RL ('B lymphocyte, precursor') ( 25 ) , RPMI-8266 (plasma cell) ( 25 ) , SU-DHL-6 (B lymphocyte) ( 25 ) , U266 (plasma cell) ( 25 ) , Vero E6-S ('epithelial, kidney') ( 1 )

Upstream Regulation
Regulatory protein:	AurA (mouse) ( 23 )
Kinases, in vitro:	AurA (human) ( 4 , 23 )
Treatments:	BI2536 ( 31 ) , ischemia ( 7 ) , metastatic potential ( 32 ) , nocodazole ( 42 )

Downstream Regulation
Effects of modification on biological processes:	apoptosis, inhibited ( 23 ) , cell growth, induced ( 23 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
3	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
4	Gallini S, et al. (2016) NuMA Phosphorylation by Aurora-A Orchestrates Spindle Orientation. Curr Biol 26, 458-69 26832443 Curated Info
5	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
6	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
7	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
8	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
9	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
10	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
11	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
12	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
13	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
14	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
15	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
16	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
17	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
18	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
19	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
20	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
21	Rikova K (2013) CST Curation Set: 18860; Year: 2012; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT Curated Info
22	Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT Curated Info
23	Toughiri R, Li X, Du Q, Bieberich CJ (2013) Phosphorylation of NuMA by Aurora-A kinase in PC-3 prostate cancer cells affects proliferation, survival, and interphase NuMA localization. J Cell Biochem 114, 823-30 23097092 Curated Info
24	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
25	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
26	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
27	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
28	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
29	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
30	Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457 20860994 Curated Info
31	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
32	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
33	Guo A (2010) CST Curation Set: 9972; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
34	Guo A (2010) CST Curation Set: 9968; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
35	Guo A (2010) CST Curation Set: 9970; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
36	Guo A (2010) CST Curation Set: 9975; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
37	Guo A (2010) CST Curation Set: 9969; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
38	Guo A (2010) CST Curation Set: 9973; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
39	Guo A (2010) CST Curation Set: 9971; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
40	Guo A (2010) CST Curation Set: 9974; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
41	Possemato A (2010) CST Curation Set: 9155; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
42	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
43	Malik R, et al. (2009) Quantitative analysis of the human spindle phosphoproteome at distinct mitotic stages. J Proteome Res 8, 4553-63 19691289 Curated Info
44	Possemato A (2009) CST Curation Set: 6922; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
45	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
46	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info